Howard McLeod
Howard McLeod
Medical Director, Moffitt Cancer Center
Verified email at moffitt.org
TitleCited byYear
Pharmacogenomics—drug disposition, drug targets, and side effects
WE Evans, HL McLeod
New England journal of medicine 348 (6), 538-549, 2003
20592003
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ...
New England Journal of Medicine 352 (22), 2285-2293, 2005
15522005
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
7732008
Doxorubicin pathways: pharmacodynamics and adverse effects
CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ...
Pharmacogenetics and genomics 21 (7), 440, 2011
6732011
Genomics and drug response
L Wang, HL McLeod, RM Weinshilboum
New England Journal of Medicine 364 (12), 1144-1153, 2011
5652011
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ...
Pharmacogenetics and Genomics 11 (3), 217-221, 2001
5252001
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ...
Journal of clinical oncology 22 (9), 1564-1571, 2004
5082004
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters
JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod
Journal of the National Cancer Institute 99 (17), 1290-1295, 2007
4752007
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
HL McLeod, EY Krynetski, MV Relling, WE Evans
Leukemia 14 (4), 567, 2000
4732000
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod
Clinical pharmacokinetics 44 (3), 279-304, 2005
4642005
Platinum neurotoxicity pharmacogenetics
SR McWhinney, RM Goldberg, HL McLeod
Molecular cancer therapeutics 8 (1), 10-16, 2009
4362009
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ...
Annals of internal medicine 129 (9), 716-718, 1998
4261998
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern, HL McLeod
Anti-cancer drugs 16 (8), 797-803, 2005
4232005
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero
The Journal of clinical investigation 98 (3), 610-615, 1996
4161996
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, HL McLeod
Thrombosis and haemostasis 91 (01), 87-94, 2004
3782004
PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy
HL McLeod, WE Evans
Annual review of pharmacology and toxicology 41 (1), 101-121, 2001
3712001
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.
ESR Collie-Duguid, SC Pritchard, RH Powrie, J Sludden, DA Collier, T Li, ...
Pharmacogenetics 9 (1), 37-42, 1999
3701999
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002
3552002
Strategies for enzyme/prodrug cancer therapy
G Xu, HL McLeod
Clinical Cancer Research 7 (11), 3314-3324, 2001
3202001
The thiopurine S-methyltransferase gene locus–implications for clinical pharmacogenomics
HL McLeod, C Siva
Pharmacogenomics 3 (1), 89-98, 2002
3152002
The system can't perform the operation now. Try again later.
Articles 1–20